Get the Stockscreener App
0.7503
4.21%
0.0303
Pre-market:
.76
0.0097
+1.29%
Genenta Science Spa Adr stock is traded at $0.7503, with a volume of 91,031.
It is up +4.21% in the last 24 hours and down -24.97% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$0.72
Open:
$0.7696
24h Volume:
91,031
Relative Volume:
0.09
Market Cap:
$17.58M
Revenue:
-
Net Income/Loss:
$-9.46M
P/E Ratio:
-1.4677
EPS:
-0.5112
Net Cash Flow:
$-10.57M
1W Performance:
+8.74%
1M Performance:
-24.97%
6M Performance:
-75.99%
1Y Performance:
-80.91%
1-Day Range:
$0.6633
$0.785
1-Week Range:
$0.59
$0.785
52-Week Range:
$0.59
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
0.7503 | 16.87M | 0 | -9.46M | -10.57M | -0.5112 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge - TipRanks
GNTA Stock Price, Quote & Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business - Finviz
11 Best Italian Stocks to Buy in 2026 - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE) - The Globe and Mail
Genenta Science Piv A Strategic Shift from Biotech to Defense - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Genenta Science to Rebrand as Saentra Forge and Enters Defense Sector with A.T.C. Stake, While Suing Enea Tech Biomedical - The Globe and Mail
Genenta Science stock soars on strategic pivot to defense sector By Investing.com - Investing.com Nigeria
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and BioLife Solutions (BLFS) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened - Defense World
Operating cash flow per share of Genenta Science SpA Sponsored ADR – FWB:K5F - TradingView — Track All Markets
Return on equity % of Genenta Science SpA Sponsored ADR – LSX:A3C9EK - TradingView
Healthy Upside Potential: Genenta Science SpA ADR (GNTA) - Setenews
Genenta Science stock soars after update on glioblastoma treatment study By Investing.com - Investing.com Australia
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewswire Inc.
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Candlestick signals on Genenta Science S.p.A. Depositary Receipt stock todayProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Genenta Science Expands Board and Corporate Purpose Following Shareholders’ Meeting - MSN
Weiss Ratings Reiterates Sell (D-) Rating for Genenta Science (NASDAQ:GNTA) - MarketBeat
Genenta Science (NASDAQ:GNTA) Stock Price Down 4.7%What's Next? - MarketBeat
Genenta Science Appoints New Board Member and Confirms CEO - MSN
Genenta Science Secures $15 Million in Registered Direct Offering - The Globe and Mail
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - inkl
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com India
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com
Genenta Science stock plunges after $15 million ADS offering - Investing.com
Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials - Investing.com Philippines
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade
United States shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com India
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):